Research programme: antiviral therapeutics - Ennaid Therapeutics
Latest Information Update: 16 Feb 2016
At a glance
- Originator Ennaid Therapeutics
- Class Peptides
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chikungunya virus infections; Dengue; West Nile virus infections; Zika virus infection
Most Recent Events
- 16 Feb 2016 Preclinical trials in Chikungunya virus infections, Dengue, West Nile virus infection, and Zika virus infection in USA (Parenteral)